TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialResearch in context

TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialResearch in context

Summary: Background: Trifluridine-tipiracil has shown a survival benefit compared with placebo in patients with chemorefractory metastatic esophago-gastric adenocarcinoma. We aimed to compare the efficacy of trifluridine-tipiracil plus bevacizumab vs trifluridine-tipiracil monotherapy in pre-treate...

Full description

Bibliographic Details
Main Authors: Lene Baeksgaard Jensen, Mette Yilmaz, Marianne Nordsmark, Sören Möller, Ida Coordt Elle, Morten Ladekarl, Camilla Qvortrup, Per Pfeiffer
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:EClinicalMedicine
Subjects:
Gastroesophageal
Cancer
Metastatic
Trifluridine-tipiracil
Bevacizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024001007

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024001007

Similar Items